Singular Genomics Systems Stock In The News

OMIC Stock  USD 21.90  0.09  0.41%   
Our overall analysis of Singular Genomics' news coverage and content from conventional and social sources shows investors' bearish mood towards Singular Genomics Systems. The specific impact of Singular Genomics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Singular Genomics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Singular Genomics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Singular Genomics Backtesting and Singular Genomics Hype Analysis.

Singular Genomics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/14/2780476/0/en/Singular-Genomics-Reports-Recent-Highlights-and-Third-Quarter-2023-Financial-Results.html
 Neutral
Macroaxis News: globenewswire.com
Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023
https://www.globenewswire.com/news-release/2023/10/24/2766054/0/en/Singular-Genomics-to-Report-Third-Quarter-2023-Financial-Results-on-November-14-2023.html
 Neutral
Yahoo News
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
https://finance.yahoo.com/news/beware-3-biotech-stocks-waving-152822395.html
 Neutral
Macroaxis News: globenewswire.com
Singular Genomics to Present at the Gilmartin Group Emerging Growth Company Showcase
https://www.globenewswire.com/news-release/2023/09/08/2740058/0/en/Singular-Genomics-to-Present-at-the-Gilmartin-Group-Emerging-Growth-Company-Showcase.html
 Bullish
Macroaxis News: globenewswire.com
Singular Genomics Reports Recent Highlights and Second Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/08/09/2722078/0/en/Singular-Genomics-Reports-Recent-Highlights-and-Second-Quarter-2023-Financial-Results.html
 Neutral
Macroaxis News: globenewswire.com
Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors
https://www.globenewswire.com/news-release/2023/08/08/2721161/0/en/Singular-Genomics-Appoints-Genomics-Veteran-Marcia-Eisenberg-Ph-D-to-Board-of-Directors.html
 Bullish
Yahoo News
Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors
https://finance.yahoo.com/news/singular-genomics-appoints-genomics-veteran-200500770.html
 Bullish
Macroaxis News: globenewswire.com
Singular Genomics Announces Participation in the UBS MedTech, Tools and Genomics Summit
https://www.globenewswire.com/news-release/2023/08/02/2717357/0/en/Singular-Genomics-Announces-Participation-in-the-UBS-MedTech-Tools-and-Genomics-Summit.html
 Neutral
Macroaxis News: globenewswire.com
Singular Genomics to Report Second Quarter 2023 Financial Results on August 9, 2023
https://www.globenewswire.com/news-release/2023/07/26/2711647/0/en/Singular-Genomics-to-Report-Second-Quarter-2023-Financial-Results-on-August-9-2023.html
 Neutral
Macroaxis News: globenewswire.com
Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference
https://www.globenewswire.com/news-release/2023/06/01/2680817/0/en/Singular-Genomics-to-Present-at-the-Goldman-Sachs-Global-Healthcare-Conference.html
 Bullish

Singular Genomics Systems Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Singular and other traded companies coverage with news coverage. We help investors stay connected with Singular headlines for the 30th of November to make an informed investment decision based on correlating the impacts of news items on Singular Stock performance. Please note that trading solely based on the Singular Genomics Systems hype is not for everyone as timely availability and quick action are needed to avoid losses.
Singular Genomics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Singular Genomics Systems investors visualize upcoming and past events in order to time the market based on Singular Genomics Systems noise-free hype analysis.
Singular Genomics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Singular earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Singular Genomics that are available to investors today. That information is available publicly through Singular media outlets and privately through word of mouth or via Singular internal channels. However, regardless of the origin, that massive amount of Singular data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Singular Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Singular Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Singular Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Singular Genomics alpha.

Singular Largest EPS Surprises

Earnings surprises can significantly impact Singular Genomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-09
2022-06-30-0.38-0.340.0410 
2022-03-02
2021-12-31-0.31-0.270.0412 
2023-11-14
2023-09-30-0.38-0.310.0718 
2022-11-07
2022-09-30-0.41-0.330.0819 
2023-03-02
2022-12-31-0.43-0.290.1432 
2021-08-03
2021-06-30-0.2-0.43-0.23115 
View All Earnings Estimates

Singular Genomics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Singular Genomics Systems Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
Macroaxis News
26th of November 2024
Disposition of 250 shares by Eli Glezer of Singular Genomics subject to Rule 16b-3
at MacroaxisInsider 
Gurufocus Stories at Macroaxis
12th of November 2024
Disposition of 1212 shares by Andrew Spaventa of Singular Genomics subject to Rule 16b-3
at gurufocus.com 
Macroaxis News
6th of November 2024
Will Singular Genomics private investors stop to exit in December
at Macroaxis 
Macroaxis News
17th of October 2024
Acquisition by Ropp Sam of 100000 shares of Singular Genomics at 0.5355 subject to Rule 16...
at MacroaxisInsider 
Macroaxis News
2nd of October 2024
Acquisition by Jyotsna Ghai of 1666 shares of Singular Genomics subject to Rule 16b-3
at MacroaxisInsider 
Investing News at Macroaxis
18th of September 2024
Acquisition by Tang Kevin of 32000 shares of Singular Genomics at 17.21 subject to Rule 16...
at investing.com 
Investing News at Macroaxis
17th of September 2024
Singular genomics CEO sells stock worth over 2,000 to cover taxes
at investing.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Singular Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Singular Genomics' short interest history, or implied volatility extrapolated from Singular Genomics options trading.
When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(34.68)
Revenue Per Share
1.107
Quarterly Revenue Growth
0.459
Return On Assets
(0.24)
Return On Equity
(0.52)
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.